(Q51346295)

English

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

scientific article published on 30 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

author name string

W Y Lee

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

K W Min

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

V K Shivane

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

A R Sosale

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

H C Jang

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

C H Chung

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

I S Nam-Goong

8

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

J A Kim

9

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

S W Kim

10

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

Gemigliptin Study 006 Group

11

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

publication date

30 January 2013

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

15

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

523-530

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12060

21 January 2018

Identifiers

10.1111/DOM.12060

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/23320436

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51346295&oldid=1234803310"